Phase 2 Study of Povetacicept for Generalized Myasthenia Gravis
This study is testing an investigational drug called Povetacicept in adults with generalized myasthenia gravis (gMG), a condition causing muscle weakness. Researchers want to see how Povetacicept affects the body and to check its safety and any side effects. You might receive Povetacicept or a placebo (an inactive substance). To join, you must be between 18 and 80 years old and have a diagnosis of generalized myasthenia gravis with moderate to severe muscle weakness. The study will measure changes in certain proteins in your blood and track any adverse events. The study plans to enroll 30 participants, but its current recruitment status is unclear.
- Study design
- This is an interventional Phase 2 study that plans to enroll 30 participants. Participants will receive either Povetacicept or a placebo.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Safety and side effects will be monitored for up to 116 weeks (about 2 years and 2 months) from the start of the study.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
At a glance
Conditions
Where it's being run
26 sites across 11 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Percent change in Total Immunoglobulin G (IgG)Baseline and At Week 12
- Safety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)From Baseline Up to Week 116